Chardan Capital Estimates Immunic FY2026 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Investment analysts at Chardan Capital issued their FY2026 earnings per share estimates for shares of Immunic in a research report issued on Monday, September 29th. Chardan Capital analyst R. Li expects that the company will post earnings per share of ($0.05) for the year. Chardan Capital currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Several other analysts also recently weighed in on IMUX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research report on Friday, September 26th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Thursday, September 25th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $9.50.

Immunic Stock Performance

Immunic stock opened at $0.96 on Thursday. Immunic has a one year low of $0.56 and a one year high of $1.73. The company has a 50-day simple moving average of $0.89 and a 200-day simple moving average of $0.92. The firm has a market capitalization of $95.03 million, a P/E ratio of -1.02 and a beta of 1.56.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Aberdeen Group plc grew its stake in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after purchasing an additional 7,184,457 shares during the last quarter. Millennium Management LLC boosted its holdings in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after buying an additional 479,846 shares in the last quarter. Focus Partners Wealth grew its position in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after buying an additional 415,104 shares during the last quarter. 683 Capital Management LLC grew its position in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after buying an additional 200,000 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares in the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.